Objectives In previous influenza pandemics, bacterial co-infections have been a major cause
of mortality. We aimed to evaluate the burden of co-infections in patients with COVID-19. …

Background. Administration of convalescent plasma, serum, or hyperimmune immunoglobulin
may be of clinical benefit for treatment of severe acute respiratory infections (SARIs) of …

Background Specific treatments for influenza are limited to neuraminidase inhibitors and
adamantanes. Corticosteroids show evidence of benefit in sepsis and related conditions, most …

Background Coronavirus disease 2019 (COVID-19) is associated with diffuse lung damage.
Corticosteroids may modulate immune-mediated lung injury and reducing progression to …

Background: In the assessment of severity in community acquired pneumonia (CAP), the
modified British Thoracic Society (mBTS) rule identifies patients with severe pneumonia but not …

Importance Effective therapies for patients with coronavirus disease 2019 (COVID-19) are
needed, and clinical trial data have demonstrated that low-dose dexamethasone reduced …

On 24 th November 2021, the sequence of a new SARS-CoV-2 viral isolate Omicron-B.1.1.529
was announced, containing far more mutations in Spike (S) than previously reported …

OF RECOMMENDATIONS A summary of the initial management of patients admitted to
hospital with suspected community acquired pneumonia (CAP) is presented in fig 8. Tables 4 …

Background Lopinavir–ritonavir has been proposed as a treatment for COVID-19 on the basis
of in vitro activity, preclinical studies, and observational studies. Here, we report the results …

Background Microbiological characterisation of co-infections and secondary infections in
patients with COVID-19 is lacking, and antimicrobial use is high. We aimed to describe …